Biomagnetic Solutions

founded in 2011 by paul a. liberti, phd, biomagnetic solutions (bms) has a 30 year history pioneering immuno-magnetic cell separation systems. prior to bms, liberti founded immunicon (nasdaq: immc) where he developed the ferrofluids & immuno-magnetic systems for cellsearch©, the only fda-approved circulating tumor cell (ctc) assay. bms has developed clinical-grade ferrofluids & clinical-scale immuno-magnetic cell separation platforms for: car-t cell therapies and cd34+ stem cell isolations for gene therapy (gt) and regenerative medicine applications. bms is also developing a very rapid, gentle, highly-sensitive, novel front-end isolation system for ctc & rare cells with its proprietary 5th-generation ferrite-based nanoparticles (ferrofluids) using proprietary principles never previously applied to cells. bms also supplies its market-tested proprietary 5th gen. ferrofluids for high-end research market applications. having pioneered ferrofluid development & the design & manufacture of no